<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932916</url>
  </required_header>
  <id_info>
    <org_study_id>DON101-CTP</org_study_id>
    <nct_id>NCT03932916</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects</brief_title>
  <official_title>Evaluation of Safety and Pharmacokinetic Profiles of a Single-dose HHT201 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Synergy Pharmaceutical Sciences Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Synergy Pharmaceutical Sciences Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and pharmacokinetic profiles of HHT201
      in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to evaluate the safety, pharmacokinetics and to determine the potential dose
      limiting toxicity of HHT201 in healthy subjects between the ages of 20-60, 6 in 17mg dose
      group and 20 in 34mg dose group. Another 12 subjects will be administered to a tablet of 5mg
      Donepezil Hydrochloride to get the PK profile of Donepezil as reference. Eligible subjects
      will be accepted into the protocol after review and providing voluntary written informed
      consent forms and completion of a comprehensive medical, physical examination, and routine
      laboratory assessment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of Donepezil</measure>
    <time_frame>Blood samples collected over a 29 days period</time_frame>
    <description>Area under the concentration-time curve from time zero to time of last measurable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Donepezil</measure>
    <time_frame>Blood samples collected over a 29 days period</time_frame>
    <description>Maximum observed concentration of drug substance in plasma</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>AD</condition>
  <arm_group>
    <arm_group_label>experimental group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HHT201 17mg injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HHT201 34mg injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil Hydrochloride oral tablet 5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil pamoate</intervention_name>
    <description>6 in 17mg dose group and 20 in 34mg dose group, all subjects will be administered to an injection of Donepezil pamoate.</description>
    <arm_group_label>experimental group 1</arm_group_label>
    <arm_group_label>experimental group 2</arm_group_label>
    <other_name>HHT201</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil Hydrochloride</intervention_name>
    <description>12 subjects will be administered to a tablet of 5mg Donepezil Hydrochloride.</description>
    <arm_group_label>experimental group 3</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese healthy subjects, male or female

          -  between the ages of 20 and 60 years

          -  A body mass index (BMI), calculated as weight in kg/(height in m)², from 19 to 28
             kg/m², and female weight≥45kg, male weight≥50kg

          -  Able to provide written informed consent forms

        Exclusion Criteria:

          1. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal,
             endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic,
             immunologic, lipid metabolism disorders

          2. Resting pulse rate &lt;55/min or &gt;100/min; Sitting systolic blood pressure &lt;90mmHg or
             &gt;140mmHg, diastolic blood pressure &lt;60mmHg or &gt;90mmHg

          3. ALT or Cr, BUN exceeding the upper limit of normal value; test results of urine
             protein was &quot;++&quot;

          4. Clinically significant ECG abnormalities in screening or baseline, such as male QTc
             interval ≥450ms and female QTc interval ≥470ms, and were considered inappropriate for
             inclusion by the researchers

          5. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface
             antigen (HBsAg), or hepatitis C antibody

          6. History or presence of drug or alcohol abuse

          7. Positive pregnancy test result, or plan to be pregnant if female

          8. An unwillingness or inability to comply with food and beverage restrictions within 24
             hours prior to dosing

          9. Participation in any other investigational drug trial within 30 days prior to
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huafang Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huafang Li, PhD</last_name>
    <phone>021-34289888</phone>
    <phone_ext>3128</phone_ext>
    <email>lhlh_5@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai mental health center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huafang Li, PhD</last_name>
      <phone>021-34289888</phone>
      <phone_ext>3128</phone_ext>
      <email>lhlh_5@163.com</email>
    </contact>
    <investigator>
      <last_name>Huafang Li, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>April 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

